BSEBoard Meeting3d ago · 24 Jul 2026, 07:25 pm
Aarti Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/07/2026 ,inter alia, to consider and approve Financial results for the quarter ....
Aarti Drugs Ltd · 524348
✦ AI SummaryResults
Aarti Drugs Ltd has scheduled a board meeting on July 31, 2026, to consider and approve financial results for the quarter ended June 30, 2026.
Analysis Scores
Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact8/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Aarti Drugs Ltd - 524348 - Board Meeting Intimation for Considering The Financial Results For The Quarter Ended June 30, 2026
Attachments (1)
📄pdf
Download →
eb61279c-9347-4044-b88d-86b033ae3d34.pdf
View document text
Ref: ADL/SE/2026-27/25
July 24, 2026
To, To,
Listing/ Compliance Department Listing/ Compliance Department
BSE LTD. National Stock Exchange of India
Phiroze Jeejeebhoy Towers Limited
Dalal Street, “Exchange Plaza”, Plot No C/1,
Mumbai 400 001 G Block, Bandra Kurla Complex,
Bandra (E), Mumbai 400 051
BSE CODE: 524348 NSE SYMBOL: AARTIDRUGS
Dear Sir/ Madam,
Ref: Regulation 29 of SEBI (Listing Obligations and
Disclosure Requirements) Regulations, 2015
Sub: Intimation of Board Meeting
This is to inform you that next Board Meeting of the Board of Directors of the Company is
scheduled to be held on Friday, July 31, 2026, to consider, approve and take on record
Audited Financial Results for the Quarter ended June 30, 2026.
In pursuance to our intimation dated June 26, 2026, the trading window of the Company
shall remain closed until the expiry of 48 hours after the declaration of the said Financial
Results.
The above information is also available on the website of the Company:
www.aartidrugs.com
You are requested to take the same on records.
Thanking you,
Yours Faithfully,
FOR AARTI DRUGS LIMITED
RUSHIKESH DEOLE
COMPANY SECRETARY & COMPLIANCE OFFICER
ICSI M. NO. F12932